Rotarod impairment: Catalepsy-like screening test for antipsychotic side effects

International Journal of Neuroscience

Volumn 119, Issue 10, 2009, Pages 1509-1522

  Kirschbaum, Katrin M ^a   Hiemke, Christoph ^a   Schmitt, Ulrich ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Antipsychotics; Catalepsy; Extrapyramidal side effects; Mouse; Rotarod

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; DIAZEPAM; DOMPERIDONE; HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE;

ARTICLE; CATALEPSY; DRUG SCREENING; EXPERIMENTAL MOUSE; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; PERFORMANCE; SCREENING TEST; SENSITIVITY AND SPECIFICITY;

ANIMALS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FREEZING REACTION, CATALEPTIC; MALE; MICE; MOTOR ACTIVITY; ROTAROD PERFORMANCE TEST; STATISTICS AS TOPIC; TIME FACTORS;

EID: 70350452743     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.1080/00207450902984002     Document Type: Article

References (31)

1. Ahlenius, S.,&Hillegaart, V. (1986). Involvement of extrapyramidal motor mechanisms in the suppression of locomotor activity by antipsychotic drugs: A comparison between the effects produced by pre- and post-synaptic inhibition of dopaminergic neurotransmission. Pharmacology Biochemistry & Behaviour, 24, 1409-1415.
2. Andersen, H. L., & Kilpatrick, I. C. (1996). Prevention by (+/-)-8-hydroxy-2-(din-propylamino)tetralin of both catalepsy and the rises in rat striatal dopamine metabolism caused by haloperidol. British Journal of Pharmacology, 118, 421-427.
3. Arnt, J., & Skarsfeldt, T. (1998). Do novel antipsychotics have similar pharmacological characteristics?Areviewof the evidence. Neuropsychopharmacology, 18, 63-101.
4. Bardin, L., Kleven, M. S., Barret-Grevoz, C., Depoortere, R., & Newman-Tancredi, A. (2006). Antipsychotic-like vs. cataleptogenic actions in mice of novel antipsychotics having D(2) antagonist and 5-HT(1A) agonist properties. Neuropsychopharmacology, 31, 1869-1879.
5. Barnes, D. E., Robinson, B., Csernansky, J. G., & Bellows, E. P. (1990). Sensitization versus tolerance to haloperidol-induced catalepsy: Multiple determinants. Pharmacology Biochemistry & Behaviour, 36, 883-887.
6. Bristow, L. J., Collinson, N., Cook, G. P., Curtis, N., Freedman, S. B., Kulagowski, J. J., et al. (1997). L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioural tests. The Journal of Pharmacology and Experimental Therapeutics, 283, 1256-1263.
7. Correll, C. U., Leucht, S., & Kane, J. M. (2004). Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. American Journal of Psychiatry, 161, 414-425.
8. Delcker, A., Schoon, M. L., Oczkowski, B., & Gaertner, H. J. (1990). Amisulpride versus haloperiol in treatment of schizophrenic patients-results of a double-blind study. Pharmacopsychiatry, 23, 125-130.
9. El Ela, A. A., Hartter, S., Schmitt, U., Hiemke, C., Spahn-Langguth, H., & Langguth, P. (2004). Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds-implications for pharmacokinetics of selected substrates. Journal of Pharmacy & Pharmacology, 56, 967-975.
10. Essig, E. C., & Kilpatrick, I. C. (1991). Influence of acute and chronic haloperidol treatment on dopamine metabolism in the rat caudate-putamen, prefrontal cortex and amygdala. Psychopharmacology, 104, 194-200.
11. Green, B. (2004). Focus on aripiprazole. Current Medical Research & Opinion, 20, 207-213.
12. Hoyer, D., Hannon, J. P., & Martin, G. R. (2002). Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacology Biochemistry & Behaviour, 71, 533-554.
13. Kelly, M. A., Rubinstein, M., Phillips, T. J., Lessov, C. N., Burkhart-Kasch, S., Zhang, G., et al. (1998). Locomotor activity in D2 dopamine receptor-deficient mice is determined by gene dosage, genetic background, and developmental adaptations. Journal of Neuroscience, 18, 3470-3479.
14. Kikuchi, T., Tottori, K., Uwahodo, Y., Hirose, T., Miwa, T., Oshiro, Y., et al. (1995). 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro- 2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. The Journal of Pharmacology and Experimental Therapeutics, 274, 329-336.
15. Köhler, C., Ogren, S. O., Haglund, L., & Angeby, T. (1979). Regional displacement by sulpiride of [3H]spiperone binding in vivo biochemical and behavioural evidence for a preferential action of limbic and nigral dopamine receptors. Neuroscience Letters, 13, 51-56.
16. Korpi, E. R.,Koikkalainen, P.,Vekovischeva,O.Y., Makela, R., Kleinz, R., Uusi-Oukari, M., et al. (1999). Cerebellar granule-cell-specific GABAA receptors attenuate benzodiazepine-induced ataxia: Evidence from alpha 6-subunit-deficient mice. European Journal of Neuroscience, 11, 233-240.
17. Kralic, J. E., O'Buckley, T. K., Khisti, R. T., Hodge, C. W., Homanics, G. E., & Morrow, A. L. (2002). GABA(A) receptor alpha-1 subunit deletion alters receptor subtype assembly, pharmacological, and behavioral responses to benzodiazepines and zolpidem. Neuropharmacology, 43, 685-694.
18. Marder, S. R., McQuade, R. D., Stock, E., Kaplita, S., Marcus, R., Safferman, A. Z., et al. (2003). Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophrenia Reserch, 61, 123-136. (Pubitemid 36513927)
19. Meltzer, H. Y., Li, Z., Kaneda, Y., & Ichikawa, J. (2003). Serotonin receptors: their key role in drugs to treat schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 27, 1159-1172.
20. Mishima, K., Tanoue, A., Tsuda, M., Hasebe, N., Fukue, Y., Egashira, N., et al. (2004) Characteristics of behavioural abnormalities in alpha1d-adrenoceptors deficient mice. Behavioural Brain Research, 152, 365-373.
21. Nakai, S., Hirose, T., Uwahodo, Y., Imaoka, T., Okazaki, H., Miwa, T., et al. (2003). Diminished catalepsy and dopamine metabolism distinguish aripiprazole from haloperidol or risperidone. European Journal of Pharmacology, 472, 89-97.
22. Perrault, G. H., Depoortere, R., Morel, E., Sanger, D. J., & Scatton, B. (1997). Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. The Journal of Pharmacology and Experimental Therapeutics, 280, 73-82. (Pubitemid 27171390)
23. Pertwee, R. G. (1972). The ring test:Aquantitative method for assessing the "cataleptic" effect of cannabis in mice. British Journal of Pharmacology, 46, 753-763.
24. Sanberg, P. R. (1980). Haloperidol-induced catalepsy is mediated by postsynaptic dopamine receptors. Nature, 284, 472-473.
25. Schoemaker, H., Claustre, Y., Fage, D., Rouquier, L., Chergui, K., Curet, O., et al. (1997). Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. The Journal of Pharmacology and Experimental Therapeutics, 280, 83-97.
26. Stanley, J. L., Lincoln, R. J., Brown, T. A., McDonald, L. M., Dawson, G. R., & Reynolds,D. S. (2005). The mouse beam-walking assay offers improved sensitivity over the mouse rotarod in determining motor coordination deficits induced by benzodiazepines. Journal of Psychopharmacology, 19, 221-227.
27. Stone, E.A., Rosengarten, H., Lin,Y.,&Quatermain, D. (2001). Pharmacological blockade of brain alpha1-adrenoceptors as measured by ex vivo [3H] prazosin binding is correlated with behavioural immobility. European Journal of Pharmacology, 420, 97-102.
28. Tada, M., Shirakawa, K., Matsuoka, N., & Mutoh, S. (2004). Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine. Psychopharmacology, 176, 94-100.
29. Tsujikawa, K., Dan, Y., Nogawa, K., Sato, H., Yamada, Y., Murakami, H., et al. (2003). Potentiation of domperidone-induced catalepsy by a P-glycoprotein inhibitor, cyclosporin A. Biopharmacology and Drug Disposition, 24, 105-114.
30. Wadenberg, M.-L. G., Kapur, S., Soliman, A., Jones, C., & Vaccarino, F. (2000). Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology, 150, 422-479.
31. Zivkovic, B., Guidotti, A., Revuelta, A., & Costa, E. (1975). Effect of thioridazine, clozapine and other antipsychotics on the kinetic state of tyrosine hydroxylase and on the turnover rate of dopamine in striatum and nucleus accumbens. The Journal of Pharmacology and Experimental Therapeutics, 194, 37-46.